Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies

Set Alert for Companies

Astellas Stays Ahead of Daiichi Sankyo In AML With CHMP Nod For Xospata

A positive opinion for its FLT3 inhibitor for acute myeloid leukemia gives Astellas a further advantage over its Japanese competitor's same-class offering, quizartinib.

Drug Review Cancer

Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA

Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.

StartUps and SMEs Financing

Themis CEO: Chikungunya Vaccine Could Be Approved In Two Years

Themis Bioscience CEO says the biotech’s €40m Series D financing will fund pivotal trials for its lead vaccine candidate for chikungunya and advance its oncology franchise.

Commercial Companies

Novartis Says SMA Baby Death Not Due To Zolgensma

The Swiss major has new data on its SMA gene therapy which has been found not to be the cause of the death of a six-month-old patient earlier this year.

Gene Therapy Neurology

Autolus Faces Life After Woodford With New Czech Backer

PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.

United Kingdom Financing

Bayer Aims To Take AI-Driven One Drop Beyond Diabetes

Bayer is boosting its AI drive by investing in One Drop’s digital platform and hopes to advance outcomes in oncology, heart disease and women’s health with data-driven solutions.

 

Digital Health Companies

Versantis Gets Cash For Toxin 'Undelivery' Product

Emerging Company Profile: CHF16m for Swiss firm that engineers liposomes to capture toxins and protect the organs of patients with acute liver failure.

 

StartUps and SMEs Companies

IPF Failure Sets Back Biogen’s Diversification Efforts

The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.

Clinical Trials Business Strategies

Purdue's Opioid Rescue Drug Development To Continue Under A New Company

Purdue proposes continuing the development of nalmefene hydrochloride and other products under a new company that would provide the products at no or low cost.

Companies Research & Development
See All
Advertisement
UsernamePublicRestriction

Register